Hilary Kramer, editor of GameChangerStocks.com, is not impressed at all by the current market or its prospects for the future. But even so, she says there are individual stocks that can do well, even in our range-bound market. Among them: a few biotech/medical equipment companies. Among her picks: Jazz Pharmaceuticals (JAZZ), Dendreon (DNDN) and TranS1(TSON).
Jazz, says Kramer, has a drug, called Xyrem, which has been used for patients with narcolepsy, to help them from being less sleepy during the day. That drug, says Kramer, is now being repackaged for fibromyalgia, giving the drug a second life and the company a huge revenue opportunity.
Kramer also explains why shares of Dendreon, which have been on a rollercoaster ride, are now a buy and she talks about a small cap stock, TranS1, which has equipment used for patients undergoing spinal fusion surgery.
Listen to the video to see why Hilary Kramer says these stocks have upside potential -- even in this market.
Why do investors make the decisions that they do?View Course »